Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 24

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 24
---
 product candidates; |

| ● | our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; |

| ● | the ability of our management team to oversee our drug research programs; |

| ● | the need to hire additional personnel and our ability to attract and retain such personnel; |

<div align='center'>10</div>

| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third parties; |

| ● | our ability to compete with other companies who offer products that address similar issues that our future product candidates will address; |

| ● | our financial performance; |

| ● | the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under our anticipated contracts which is subject to certain risks; |

| ● | difficulties in our partners’ ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; |

| ● | our ability to restructure our operations to comply with future changes in government regulation; |

| ● | security, political and economic instability in the Middle East that could harm our business, including due to the security situation in Israel; and |

| ● | those factors referred to in our 2024 Annual Report incorporated by reference herein in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects,” as well as in our 2024 Annual Report generally, which is incorporated by reference into this prospectus. |

Forward-looking statements are based on our management’s
current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s
beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties
and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus
may turn out to be inaccurate. Important factors that may cause actual results to differ materially from